Newsroom


Please note that the Company does not update, correct or revise news releases after they have been issued. For the most current information about the Company, please refer to the most recent releases.

3/12/2017, Monday

Media Contacts:
Kristy Marks
Director, Corporate Communications, Bausch + Lomb 
kristy.marks@bausch.com
908-927-0683

Don Murphy
Zeno Group, on behalf of Bausch + Lomb
don.murphy@zenogroup.com 
212-299-8970

BAUSCH + LOMB SIGNS AGREEMENT WITH EXPRESS SCRIPTS, INC., EXPANDING INSURANCE COVERAGE OF VYZULTA™ (LATANOPROSTENE BUNOD OPHTHALMIC SOLUTION), 0.024%

BRIDGEWATER, NJ, March 12, 2018 – Bausch + Lomb, a leading global eye health company, today announced an agreement with Express Scripts, Inc. to begin coverage of VYZULTA™ (latanoprostene bunod ophthalmic solution), 0.024%. Under the agreement, VYZULTA is covered under an access position on both the commercial Express Scripts National Preferred and Basic formularies, giving access to an additional 23 million people in the United States. VYZULTA, the first prostaglandin analog with one of its metabolites being nitric oxide (NO), is indicated for the reduction of intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension.1

"We are proud of this achievement as it signifies the health care community’s recognition of the benefit VYZULTA may offer glaucoma patients," said Tracy Valorie, senior vice president and general manager, U.S. Pharmaceuticals and Surgical, Bausch + Lomb. "Bausch + Lomb is committed to providing our customers and their patients innovative medicines for prevalent eye health conditions."

Important Risk Information about VYZULTA

INDICATION AND USAGE
VYZULTA™ (latanoprostene bunod ophthalmic solution), 0.024% is a prostaglandin analog indicated for the reduction of intraocular pressure in patients with open-angle glaucoma or ocular hypertension.

IMPORTANT SAFETY INFORMATION

  • Increased pigmentation of the iris, periorbital tissue (eyelid), and eyelashes can occur. Iris pigmentation is likely to be permanent
  • Gradual changes to eyelashes, including increased length, increased thickness, and number of eyelashes, may occur. These changes are usually reversible upon treatment discontinuation
  • Most common ocular adverse reactions with incidence ≥2% are conjunctival hyperemia (6%), eye irritation (4%), eye pain (3%), and instillation site pain (2%)

Please see full prescribing information at www.bausch.com/vyzulta.

 

About Express Scripts
Express Scripts puts medicine within reach of tens of millions of people by aligning with plan sponsors, taking bold action and delivering patient-centered care to make better health more affordable and accessible.

Headquartered in St. Louis, Express Scripts provides integrated pharmacy benefit management services, including network-pharmacy claims processing home delivery pharmacy care, specialty pharmacy care, specialty benefit management, benefit-design consultation, drug utilization review, formulary management, and medical and drug data analysis services.  Express Scripts also distributes a full range of biopharmaceutical products and provides extensive cost-management and patient-care services.

About Bausch + Lomb
Bausch + Lomb, a Valeant Pharmaceuticals International, Inc. company, is a leading global eye health organization that is solely focused on protecting, enhancing and restoring people's eyesight. Its core businesses include over-the-counter supplements, eye care products, ophthalmic pharmaceuticals, contact lenses, lens care products, ophthalmic surgical devices and instruments. Bausch + Lomb develops, manufactures and markets one of the most comprehensive product portfolios in our industry, which is available in more than 100 countries.


References  
1. Vyzulta™ [prescribing information]. Bridgewater, NJ: Bausch & Lomb Incorporated; 2017.

VYZ.0122.USA.18

Print

Number of views (1968)/Comments (0)

x